Clinical Trial Update: A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes [Phase 2]

View source ↗

Summary

Phase IIa proof-of-concept trial of NC-503 in adults with type 2 diabetes mellitus has been completed. The study was sponsored by Bellus Health Inc. (a GSK comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Type 2 Diabetes Mellitus

Drugs mentioned

• NC-503 (NC-503)

Snippet

Sponsor: Bellus Health Inc. - a GSK company | Conditions: Diabetes Mellitus, Type 2, Metabolic Syndrome X | Phase 2 | Status: COMPLETED